Drug Profile
SOBI 003
Alternative Names: Modified recombinant human sulphamidase; Recombinant-sulfamidase-Swedish-Orphan-Biovitrum; SOBI-003Latest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator Swedish Orphan Biovitrum
- Class Hydrolases; Recombinant proteins
- Mechanism of Action N-sulfoglucosamine sulfohydrolase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Mucopolysaccharidosis III
Most Recent Events
- 04 Sep 2023 Discontinued - Phase-I/II for Mucopolysaccharidosis III (In children, In infants) in Germany (IV) (Swedish Orphan Biovitrum pipeline, September 2023)
- 04 Sep 2023 Discontinued - Phase-I/II for Mucopolysaccharidosis III (In children, In infants) in Netherlands (IV) (Swedish Orphan Biovitrum pipeline, September 2023)
- 04 Sep 2023 Discontinued - Phase-I/II for Mucopolysaccharidosis III (In children, In infants) in Turkey (IV) (Swedish Orphan Biovitrum pipeline, September 2023)